{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:07:37Z","timestamp":1778630857911,"version":"3.51.4"},"reference-count":81,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer-associated thrombosis (CAT) remains a major cause of morbidity and mortality in patients with malignancy. Direct oral anticoagulants (DOACs) have expanded the therapeutic armamentarium for CAT and are now widely used as alternatives to low molecular weight heparins (LMWHs). However, the increasing complexity of contemporary oncologic care has heightened concerns regarding clinically relevant drug\u2013drug interactions (DDIs). All DOACs are substrates of P-glycoprotein, and some undergo partial metabolism via cytochrome P4503A4, rendering them more susceptible to pharmacokinetic (PK) modulation by anticancer agents. Moreover, several antineoplastic drugs exert intrinsic prothrombotic or hemorrhagic effects, thereby introducing pharmacodynamic interactions that may further destabilize the already dysregulated hemostatic system in cancer. Despite these theoretical concerns, evidence from randomized trials and real-world studies remains limited and largely derived from subgroup analyses, PK investigations in healthy volunteers, or retrospective registries. Consequently, the true clinical magnitude of DDIs in CAT remains incompletely defined. This review critically appraises the pharmacological basis, clinical evidence, and translational implications of DDIs between DOACs and anticancer therapies. We propose that DDIs in CAT should not be viewed solely as PK phenomena, but also as potential biological amplifiers of cancer-associated coagulopathy. Until prospective, dedicated studies become available, a structured\/individualized approach\u2014integrating thrombotic\/bleeding risk, interacting medications, and patient-specific factors\u2014is warranted.<\/jats:p>","DOI":"10.1055\/a-2860-6033","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:07:18Z","timestamp":1778627238000},"source":"Crossref","is-referenced-by-count":0,"title":["Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-6135","authenticated-orcid":false,"given":"Antonella","family":"Tufano","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corsini","sequence":"first","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences \u201cRodolfo Paoletti,\u201d University of Milan, Milan, Lombardy, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Ferri","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Padova, Padua, Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"first","affiliation":[{"name":"Unit of Medical Oncology, University of Perugia, Perugia, Umbria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Guida","sequence":"additional","affiliation":[{"name":"Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Campania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Costabile","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, University of Perugia, Perugia, Umbria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"J A Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"H K Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"151","key":"ref4","doi-asserted-by":"crossref","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why","volume":"28","author":"C J Fernandes","year":"2019","journal-title":"Eur Respir Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2016.06.033","article-title":"Epidemiology of venous thromboembolism in the Framingham Heart Study","volume":"145","author":"M K Puurunen","year":"2016","journal-title":"Thromb Res"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"A A Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0038-1676611","article-title":"Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry","volume":"119","author":"W Ageno","year":"2019","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"A Mahajan","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3324\/haematol.2023.284778","article-title":"Targeted anti-cancer agents and risk of venous thromboembolism","volume":"109","author":"M Verso","year":"2024","journal-title":"Haematologica"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ajh.26954","article-title":"Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy","volume":"98","author":"A Li","year":"2023","journal-title":"Am J Hematol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"F Petrelli","year":"2012","journal-title":"Ann Oncol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"e006072","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"A A Khorana","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"S 01","key":"ref13","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","article-title":"Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies","volume":"213","author":"F Moik","year":"2022","journal-title":"Thromb Res"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"E Donnellan","year":"2017","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"102190","DOI":"10.1016\/j.ctrv.2021.102190","article-title":"Treatment of venous thromboembolism in cancer patients: the dark side of the moon","volume":"96","author":"C Becattini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.3390\/curroncol28060453","article-title":"Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus","volume":"28","author":"M Carrier","year":"2021","journal-title":"Curr Oncol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/hae.70163","article-title":"Acquired bleeding disorders associated with immune checkpoint inhibitors: an update","volume":"32","author":"M Tuccori","year":"2026","journal-title":"Haemophilia"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"F Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"N Ferri","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2018.09.015","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions","volume":"132","author":"H Riess","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40256-013-0061-0","article-title":"New oral anticoagulants in practice: pharmacological and practical considerations","volume":"14","author":"Y Wang","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"J Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"J Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"07","key":"ref25","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"I Y Gong","year":"2013","journal-title":"Can J Cardiol"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"J Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"J Stampfuss","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"C Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"C Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/FJC.0b013e31826265b6.","article-title":"Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination","volume":"60","author":"J Mendell","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"S Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"W Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"L Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"D A Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"S Wolking","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"ref36","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"J Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"G Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"M Verso","year":"2021","journal-title":"Eur J Cancer"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ccr3.2106","article-title":"A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma","volume":"7","author":"M MA Waite","year":"2019","journal-title":"Clin Case Rep"},{"issue":"05","key":"ref42","first-page":"e2701","article-title":"Management of atrial fibrillation in patients on ibrutinib: a Cleveland Clinic experience","volume":"10","author":"S Khalid","year":"2018","journal-title":"Cureus"},{"issue":"05","key":"ref43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hon.2545","article-title":"Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: experience of 4 cases","volume":"36","author":"A Visentin","year":"2018","journal-title":"Hematol Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1758835919833867","DOI":"10.1177\/1758835919833867","article-title":"Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication","volume":"11","author":"M Bellet","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11897-020-00485-9","article-title":"The complex management of atrial fibrillation and cancer in the COVID-19 era: drug interactions, thromboembolic risk, and proarrhythmia","volume":"17","author":"M Gatti","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"N Ferri","year":"2016","journal-title":"Pharmacol Res"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"J A Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","article-title":"Clinical pharmacokinetic studies of enzalutamide","volume":"54","author":"J A Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1182\/blood-2015-06-646638","article-title":"The wacky hypercoagulable state of malignancy","volume":"126","author":"A A Khorana","year":"2015","journal-title":"Blood"},{"issue":"09","key":"ref50","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-020-00881-3","article-title":"Pharmacokinetic drug-drug interaction of apalutamide, part 2: investigating interaction potential using a physiologically based pharmacokinetic model","volume":"59","author":"A Van den Bergh","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer","volume":"59","author":"I Duran","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","article-title":"Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors","volume":"24","author":"F Saad","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"ref53","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1124\/dmd.116.070672","article-title":"In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity","volume":"44","author":"J Monbaliu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2020.09.037","article-title":"Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: a cohort study","volume":"324","author":"R Pacholczak-Madej","year":"2021","journal-title":"Int J Cardiol"},{"issue":"09","key":"ref55","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1600-6143.2004.00539.x","article-title":"CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus","volume":"4","author":"W P Lemahieu","year":"2004","journal-title":"Am J Transplant"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"D A Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/cts.12580","article-title":"Drug-drug interaction study of apixaban with cyclosporine and tacrolimus in healthy volunteers","volume":"11","author":"B Bashir","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.13934","article-title":"Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers","volume":"85","author":"A Brings","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"07","key":"ref60","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/tri.13599","article-title":"Safety and efficacy of direct-acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single-center cohort study","volume":"33","author":"A L Bixby","year":"2020","journal-title":"Transpl Int"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/10600280211025042","article-title":"Potential dexamethasone-direct oral anticoagulant drug interaction: is this a concern in COVID?","volume":"56","author":"M A Smythe","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/heartjnl-2021-319503","article-title":"Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants","volume":"108","author":"A Holt","year":"2022","journal-title":"Heart"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week","volume":"75","author":"B S Wiggins","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"A Li","year":"2019","journal-title":"Thromb Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"114823","DOI":"10.1016\/j.biopha.2023.114823","article-title":"Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients","volume":"163","author":"D AC Lanser","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"20","key":"ref66","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"R D McBane II","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"B Planquette","year":"2022","journal-title":"Chest"},{"issue":"08","key":"ref69","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/jth.15367","article-title":"Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"19","author":"T F Wang","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"15","key":"ref70","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"C J Beavers","year":"2022","journal-title":"Circulation"},{"issue":"16","key":"ref71","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"41","key":"ref72","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"A R Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"08","key":"ref73","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"A Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1055\/a-2337-4025","article-title":"Antithrombotic therapy in cancer patients with cardiovascular diseases: daily practice recommendations by the hemostasis working party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)","author":"S Parmentier","year":"2024","journal-title":"Hamostaseologie"},{"key":"ref75","first-page":"6S31","article-title":"Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer","volume":"45","author":"M Sebuhyan","year":"2020","journal-title":"J Med Vasc"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00280-019-03783-9","article-title":"Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer","volume":"83","author":"A Hoemme","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"ref77","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.12948","article-title":"Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study","volume":"93","author":"M Hunault-Berger","year":"2008","journal-title":"Haematologica"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/asheducation-2007.1.151","article-title":"Double hazard of thrombophilia and bleeding in leukemia","author":"H C Kwaan","year":"2007","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"J J Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref80","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding","volume":"36","author":"G Boriani","year":"2018","journal-title":"Hematol Oncol"},{"issue":"15","key":"ref81","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"D J Kuter","year":"2022","journal-title":"N Engl J Med"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jtha.2025.10.028","article-title":"Mechanisms of anticancer treatment-induced arterial and venous thrombosis","volume":"24","author":"P Albasanz-Garc\u00eda","year":"2026","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2860-6033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:07:35Z","timestamp":1778627255000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2860-6033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":81,"URL":"https:\/\/doi.org\/10.1055\/a-2860-6033","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}